Skip to content

KeifeRx vs Sitryx

KeifeRx logo

KeifeRx

KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegenerative diseases. #HoyaSaxa

7 employees · est. 2019 · Mclean, United States

VS
Sitryx logo

Sitryx

Harnessing the power of cell metabolism to develop groundbreaking disease-modifying therapies

48 employees · est. 2018 · Oxford, United Kingdom

Sitryx is the older company (2019 vs 2018); Sitryx is the larger of the two.

Side-by-Side Comparison

KeifeRx Sitryx
Founded
2019 2018 older
Headquarters
Mclean, United States Oxford, United Kingdom
Employees
7 48 larger
Industry
Biopharma, Biotechnology, Pharmaceutical Biotechnology, Health Care, Pharmaceutical
Funding Stage
Series A Series A
Total Funding
$6.00M $79.00M
Funding Rounds
1 3
Services
development of kinase inhibitors, clinical trials for neurodegenerative disease treatments, collaborative research for drug development Developing novel oral therapies, Restoring immune balance, Disease remission through precision immunology
Target Customers
dementia patients, patients with neurodegenerative diseases, healthcare providers in neurology, clinical researchers Patients with autoimmune and inflammatory diseases, Global biopharmaceutical companies seeking strategic partnerships
Taxonomy
BiopharmaceuticalClinical-stageNeurodegenerative DiseasesDisease-modifying TreatmentsTyrosine Kinase InhibitorsLow Dose Therapy +8 BiopharmaceuticalCell MetabolismDisease-modifying TherapeuticsImmuno-oncologyImmuno-inflammationImmunometabolism +9
Website
keiferx.com sitryx.com
KeifeRx logo

About KeifeRx

KeifeRx, founded in 2019, is an emerging biopharmaceutical company headquartered in the United States. The company specializes in developing innovative treatments for neurodegenerative and immune diseases using novel tyrosine kinase inhibitors (TKIs). By focusing on low-dose, orally delivered soluti...

Sitryx logo

About Sitryx

Sitryx is a dynamic player in the biopharmaceutical sector, leveraging the innovative capabilities of cell metabolism to pioneer novel, disease-modifying therapies focused on immuno-oncology and immuno-inflammation. Founded in 2018, the company operates from its headquarters in Oxford, UK. The core...

Also comparing in this category

Comparing more than these two?

Get KeifeRx, Sitryx and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.

How does KeifeRx compare?

A PDF of KeifeRx and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Rival Readout

Comparing competitors? We do this properly.

10 rivals, 90 days of dated moves in 7 business days: a ranked list of what matters, each with its source, ending in a 60-minute readout with your team.

Frequently Asked Questions

KeifeRx was founded in 2019, based in Mclean, United States, with 7 employees. KeifeRx, founded in 2019, is an emerging biopharmaceutical company headquartered in the United States. The company specializes in developing innovative treatments for neurodegenerative and immune dise. Sitryx was founded in 2018, based in Oxford, United Kingdom, with 48 employees. Sitryx is a dynamic player in the biopharmaceutical sector, leveraging the innovative capabilities of cell metabolism to pioneer novel, disease-modifying therapies focused on immuno-oncology and immun.
KeifeRx has raised $6.00M and Sitryx $79.00M. Latest stage: KeifeRx Series A, Sitryx Series A.
Both work in Biotechnology and Pharmaceutical and list biopharmaceutical, drug discovery and therapeutics development among their focus areas.

Compare KeifeRx with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at KeifeRx on 11 Mar 2026, and Sitryx on 6 May 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout